Patent term extensions for biologic innovators in Japan

Nature Biotechnology

Volumn 29, Issue 1, 2011, Pages 34-37

  Tessensohn, John A ^a   Yamamoto, Shusaku ^a  

^a Shusaku Yamamoto   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; HUMAN GROWTH HORMONE; HYBRID PROTEIN; LYMPHOTOXIN; TUMOR NECROSIS FACTOR;

ARTICLE; COMMERCIAL PHENOMENA; HEALTH CARE; HEALTH CARE ORGANIZATION; JAPAN; LEUKOCYTE; MARKETING; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MEDICOLEGAL ASPECT; PATENT TERM EXTENSION; PRIORITY JOURNAL;

BIOTECHNOLOGY; DRUG DISCOVERY; IMMUNOGLOBULIN G; INTELLECTUAL PROPERTY; JAPAN; PATENTS AS TOPIC; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 78651288640     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.1743     Document Type: Article

References (23)

1. Tessensohn, J.A. & Yamamoto, S. World Intell. Prop. Law Rep. 23, 31-32 (2009).
2. Connolly, C. & Shear, M.D. Discord on health care dulls luster of new pacts. Washington Post 9 July 2009, A1.
3. Anonymous. Biotech bottleneck. Washington Post 29 July 2009, A16.
4. Pollack, A. Costly drugs known as biologics prompt exclusivity debate. New York Times 22 July 2009, B1.
5. Belsey, M.J., Harris, L.M., Das, R.R. & Chertkow, J. Nat. Rev. Drug Discov. 5, 535-536 (2006).
6. Anonymous. Merck to storm Japan with generic biologics. Nihon Keizai Shimbun 3 March 2010.
7. Anonymous. nichi-Iko eyes biodrug sales in 3 years with Sanofi-Aventis' help. Nihon Keizai Shimbun 1 June 2010.
8. GlaxoSmithKline acquired the ex-Japan development and marketing rights to JCR's biosimilar JR-013, a FOB recombinant human erythropoietin kappa that has been approved for renal anaemia in kidney dialysis patients and premature infants, JCR Pharmaceuticals Co. Ltd., Press Release: Comprehensive Agreement on Biopharmaceuticals Business, Dec. 18, 2009.
9. Anonymous. Teva-Kowa, nippon Kayaku to develop generic for chemotherapy. Nihon Keizai Shimbun 20 April 2010.
10. Immunex Corp. v. Commissioner of Japan Patent Office, H-21 (gyo-ke) no. 10092 and H-21 (gyo-ke) no. 10093 dated Dec. 3, 2009, Intellectual Property High Court of Japan.
11. Wyeth, K.K. & Takeda Pharmaceutical Co. Ltd. Press release: announcing launch of EnBREL, treatment of rheumatoid arthritis. (29 March, 2005).
12. Jacobsen, T.M. & Wertheimer, A.I. Modern Pharmaceutical Industry: A Primer (Jones and Bartlett Publishers, Sudbury, MA, USA, 2010).
13. Tessensohn, J.A. & Yamamoto, S. World. Intell. Prop. Law Rep. 19, 21-22 (2005).
14. Tessensohn, J.A. & Yamamoto, S. World. Intell. Prop. Law Rep 2010/1 18-19 (2010). http://www.wipo.int/ wipo-magazine/en/2010/01/article-0007.html.
15. Japan Patent Office. Annual Report 2006 (Japanese Version) (JPO, Tokyo, 2006).
16. Japan Patent Office. Annual Report 2009 (Japanese Version) (JPO, Tokyo, 2009).
17. Schellekens, H. & Moors, E. Nat. Biotechnol. 28, 28-31 (2010).
18. US Department of Health and Human Services et al. Guidance for industry Q5E comparability of biotechnological/ biological products subject to changes in their manufacturing process. (June 2005).
19. Tessensohn, J.A. Modified-Release Drug Delivery Technology. (Rathbone, M.J. et al., eds.) 45-51 (Informa Healthcare, new York, 2008).
20. Wyeth v. Kappos, 93 U.S.P.Q. 2d 1227 (Fed. Cir. 2010).
21. Tomomi, A. et. al. Nat. Biotechnol. 25, 533-535 (2007).
22. Tessensohn, J.A. & Yamamoto, S. Biotechnol. Law Rep. 28 483-496 (2009).
23. Tessensohn, J.A. & Yamamoto, S. Nat. Biotechnol. 27, 815-818 (2009).